SHANDONG XINHUA (00719) Unit Secures Drug Registration Certificate for Ibuprofen Granules

Stock News

Yesterday

SHANDONG XINHUA PHARMACEUTICAL (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ibuprofen Granules from the National Medical Products Administration. In December 2023, Xinda Pharmaceutical submitted the application for market approval of Ibuprofen Granules to the Center for Drug Evaluation (CDE) of the NMPA, which was accepted. The certificate was granted in March 2026, with the review conclusion being approval for registration. The product is indicated for the relief of mild to moderate pain, such as headaches, joint pain, migraines, toothaches, muscle aches, nerve pain, and menstrual cramps, as well as for reducing fever caused by the common cold or influenza. Ibuprofen Granules are listed as a Category B drug in the National Reimbursement Drug List (2025 edition). According to relevant statistics, sales of ibuprofen-related formulations in China's public medical institutions reached approximately RMB 4.4 billion in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1111654461"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111654461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111654461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111654461","market":"sh","top_or_hot":-1,"title":"SHANDONG XINHUA (00719) Unit Secures Drug Registration Certificate for Ibuprofen Granules","media":"Stock News","content":"<p>SHANDONG XINHUA PHARMACEUTICAL (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ibuprofen Granules from the National Medical Products Administration. In December 2023, Xinda Pharmaceutical submitted the application for market approval of Ibuprofen Granules to the Center for Drug Evaluation (CDE) of the NMPA, which was accepted. The certificate was granted in March 2026, with the review conclusion being approval for registration. The product is indicated for the relief of mild to moderate pain, such as headaches, joint pain, migraines, toothaches, muscle aches, nerve pain, and menstrual cramps, as well as for reducing fever caused by the common cold or influenza. Ibuprofen Granules are listed as a Category B drug in the National Reimbursement Drug List (2025 edition). According to relevant statistics, sales of ibuprofen-related formulations in China's public medical institutions reached approximately RMB 4.4 billion in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA (00719) Unit Secures Drug Registration Certificate for Ibuprofen Granules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA (00719) Unit Secures Drug Registration Certificate for Ibuprofen Granules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-23 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA PHARMACEUTICAL (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ibuprofen Granules from the National Medical Products Administration. In December 2023, Xinda Pharmaceutical submitted the application for market approval of Ibuprofen Granules to the Center for Drug Evaluation (CDE) of the NMPA, which was accepted. The certificate was granted in March 2026, with the review conclusion being approval for registration. The product is indicated for the relief of mild to moderate pain, such as headaches, joint pain, migraines, toothaches, muscle aches, nerve pain, and menstrual cramps, as well as for reducing fever caused by the common cold or influenza. Ibuprofen Granules are listed as a Category B drug in the National Reimbursement Drug List (2025 edition). According to relevant statistics, sales of ibuprofen-related formulations in China's public medical institutions reached approximately RMB 4.4 billion in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1111654461","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111654461","pubTimestamp":1774255472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA PHARMACEUTICAL (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ibuprofen Granules...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份","01477":"欧康维视生物-B","BK1515":"抗疫概念","BK1191":"制药","BK1574":"生物医药B类股"},"translate_title":"山东新华(00719)子公司获得布洛芬颗粒药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"00719":1},"content_text":"SHANDONG XINHUA PHARMACEUTICAL (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ibuprofen Granules from the National Medical Products Administration. In December 2023, Xinda Pharmaceutical submitted the application for market approval of Ibuprofen Granules to the Center for Drug Evaluation (CDE) of the NMPA, which was accepted. The certificate was granted in March 2026, with the review conclusion being approval for registration. The product is indicated for the relief of mild to moderate pain, such as headaches, joint pain, migraines, toothaches, muscle aches, nerve pain, and menstrual cramps, as well as for reducing fever caused by the common cold or influenza. Ibuprofen Granules are listed as a Category B drug in the National Reimbursement Drug List (2025 edition). According to relevant statistics, sales of ibuprofen-related formulations in China's public medical institutions reached approximately RMB 4.4 billion in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}